FIPI

ArtNr	HY-12807-100mg
Hersteller	MedChem Express
CAS-Nr.	939055-18-2
Menge	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 50 mg 5 mg
Kategorie	Oncology Neuroscience Metabolism Cholesterol & Lipid Metabolism Neural Signaling Enzymes Other Fatty Acid Enzymes Inhibitors & Compound Libraries Small Molecules By Organ Bone Cancer
Typ	Inhibitors
Specific against	other
Purity	99.49
Citations	[1]Su W, et al. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol Pharmacol. 2009 Mar;75(3):437-46.\|[2]Stricker HM, et al. The phospholipase D inhibitor FIPI potently blocks EGF-induced calcium signaling in human breast cancer cells. Cell Commun Signal. 2021 Apr 8;19(1):43.\|[3]Elvers M, et al. A novel role for phospholipase D as an endogenous negative regulator of platelet sensitivity. Cell Signal. 2012 Sep;24(9):1743-52. \|[4]Stegner D, et al. Pharmacological inhibition of phospholipase D protects mice from occlusive thrombus formation and ischemic stroke--brief report. Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2212-7.
Smiles	O=C(NCCN1CCC(CC1)N2C3=CC=CC=C3NC2=O)C4=CC5=C(C=CC(F)=C5)N4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	5-Fluoro-2-indolyl deschlorohalopemide
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Phospholipase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	421.47
Product Description	FIPI is a phospholipase D (PLD) inhibitor with an IC50 for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function[1][2][3][4].
Manufacturer - Research Area	Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Solubility	DMSO: 14.67 mg/mL (ultrasonic; warming)
Manufacturer - Pathway	Metabolic Enzyme/Protease
Isoform	PLD
Clinical information	No Development Reported

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-12807-100mg-safety-datasheet.pdf